Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy

摘要

Disclosed is an ex vivo method of determining the sensitivity of a cell to a compound that modulates HER2 activity, the method comprising: (a) contacting the cell with the compound; (b) lysing the cell to produce a cellular extract; (c) determining the activation level of HER2 and p95HER2 in the cellular extract produced from the cell; and (d) comparing the activation level of HER2 and p95HER2 determined in step (c) to a first reference activation level of HER2 and p95HER2 in a compound-sensitive cell treated with the compound and to a second reference activation level of HER2 and p95HER2 in a compound-resistant cell treated with the compound, wherein the presence of a similar or lower level of HER2 and p95HER2 activation in the cellular extract compared to the first reference activation level of HER2 and p95HER2 indicates that the cell is sensitive to the compound, and wherein the presence of a similar or higher level of HER2 and p95HER2 activation in the cellular extract compared to the second reference activation level of HER2 and p95HER2 indicates that the cell is resistant to the compound.